NextCure Inc. (NASDAQ: NXTC) reported a net loss of $55.8 million for the year ended December 31 2025, translating to a loss of $19.65 per share. The company’s cash, cash equivalents, and marketable securities totaled $41.8 million at year‑end, a significant increase from the $29.1 million reported in September 2025.
While the company did not disclose a fourth‑quarter EPS, it reported a Q3 2025 loss per share of $-3.22. The full‑year loss per share of $19.65 represents a steep decline from the $4.92 loss per share recorded in the same quarter a year earlier, indicating a substantial improvement in operating performance.
Management highlighted that lower operating expenses and a less severe one‑time charge than anticipated helped drive the improved loss profile. CEO Michael Richman said, "2026 is on track to be transformational for NextCure, as we set the stage to present clinical dose escalation data from the Phase 1 trial for SIM0505." He added, "Since acquiring the program in June of 2025, we have made rapid clinical and regulatory progress and soon expect to begin enrolling platinum‑resistant ovarian cancer patients in the Phase 1 dose optimization study. To accelerate the program, we plan to double the number of U.S. trial sites and expand our footprint into multiple other countries."
The company’s cash burn remains a critical concern. With $41.8 million on hand and a burn rate that could deplete reserves before the first half‑2026 data readouts for its two Phase‑1 ADC programs, NextCure must secure additional capital before mid‑2026 to maintain its clinical pipeline and avoid a going‑concern scenario.
NextCure’s pipeline remains its core asset. The company continues to advance SIM0505, a CDH6‑targeted ADC, and LNCB74, a partner‑developed ADC. CEO Richman noted, "We have made significant progress advancing our promising ADC programs," and added, "We recently began U.S. enrollment in the Phase 1 trial for SIM0505, our CDH6 ADC, initiating at a mid‑tier dose range where multiple clinical responses were observed in China by our partner Simcere Zaiming." These developments position the company for potential milestone payments and future commercialization, but the need for new funding remains a key risk factor.
The company did not provide updated guidance for the next quarter or full year. However, the emphasis on cost control, accelerated trial expansion, and the upcoming data readouts suggests management remains cautiously optimistic about the company’s trajectory, while acknowledging the financial runway constraints that will require additional capital to sustain progress.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.